750 related articles for article (PubMed ID: 32206157)
1. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
6. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455
[TBL] [Abstract][Full Text] [Related]
9. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
10. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment.
Ontario Health
Ont Health Technol Assess Ser; 2024; 24(2):1-162. PubMed ID: 38344326
[TBL] [Abstract][Full Text] [Related]
13. Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(8):1-151. PubMed ID: 38130940
[TBL] [Abstract][Full Text] [Related]
14. Internet-Delivered Cognitive Behavioural Therapy for Post-traumatic Stress Disorder or Acute Stress Disorder: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(9):1-120. PubMed ID: 34527087
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
[TBL] [Abstract][Full Text] [Related]
16. Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(12):1-134. PubMed ID: 33240453
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(11):1-178. PubMed ID: 32194879
[TBL] [Abstract][Full Text] [Related]
19. Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(4):1-398. PubMed ID: 37637488
[TBL] [Abstract][Full Text] [Related]
20. Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(3):1-146. PubMed ID: 37284279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
